6,155
88
Adcetris + AVD and G-CSF significantly improves outcomes compared to ABVD - 4 years follow up.from ASH 2019.
Margetuximab improves progression-free survival compared to Herceptin® in patients with HER2+ metastatic breast cancer.
Kisqali prolongs survival and delays cancer progression for Pre-menopausal Hormone Receptor Positive Breast Cancer
Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer: Update from San Antonio Breast Cancer Symposia.
Selective internal radiotherapy may be effective for the down staging of patients with unresectable Cholangiocarcinoma
Brukinsa is a novel BTK inhibitor with encouraging anti-cancer activity in the management of CLL/SLL.
ASH Update - Sustained progression free and overall survival benefits with the Venclexta + Rituxan combination.
TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Tagrisso resistance mutation recently identified.
ASH 2019 update report Calquence delays CLL progression compared to Gazyva + Chlorambucil
Photodynamic therapy for neck cancer - good overview. Anyone have experience? …
Is anyones doctor recommending treatment with a checkpoint inhibitor? These seem like they could be…
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
Optune looking for others to share their experience? How long do you wear it each day? How…
Can anyone share their experience with cold cap to prevent hair loss? I have learned that i can…
